Gastrointestinal stromal tumour

The PBS subsidises imatinib and sunitinib for patients with gastrointestinal stromal tumour.

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with imatinib and sunitinib under the National Health Act 1953, section 85 for patients with gastrointestinal stromal tumour (GIST).

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing imatinib and sunitinib.

Applications

Initial

Apply for authority approval to prescribe PBS subsidised sunitinib to treat metastatic or unresectable malignant GIST in writing and either:

All applications must include the completed:

To apply for initial PBS subsidised imatinib to treat resected primary GIST with high risk of recurrence, or metastatic or unresectable malignant GIST call the PBS Complex Drugs Programs enquiry line.

Continuing

Continuing PBS subsidised sunitinib to treat metastatic or unresectable malignant GIST is Authority Required (Streamlined). It doesn’t need authority approval from us for listed quantities and/or repeats.

Continuing PBS subsidised imatinib to treat resected primary GIST with high risk of recurrence, or metastatic or unresectable malignant GIST is Authority Required (Streamlined). It doesn’t need authority approval from us for listed quantities and/or repeats.

More information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 28 August 2019

Was this page useful?
Why?
Why not?

Thank you for your feedback.